4 news items
FibroGen Reports First Quarter 2024 Financial Results
FGEN
6 May 24
evaluable patients, 20% met the criteria of a partial response, or measurable tumor reduction in size of ≥ 30%, with a median duration of response
FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape
ABBV
FGEN
3 Apr 24
evaluable patients.
20% met the criteria of a partial response, or tumor reduction in size of over 30%, with a median duration of response
FibroGen Reports Data From Fortis Therapeutics-Sponsored Phase 1 Study Of FG-3246
FGEN
2 Apr 24
patients, 20% met the criteria of a partial response, or tumor reduction in size of ≥ 30%, with a median duration of response of 7.5
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
FGEN
2 Apr 24
PSA50 response in 36% of patients
- Prev
- 1
- Next